Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) is featured in an editorial by NetworkNewsWire highlighting the significant issue of hypertension in America, affecting 108 million adults. Despite the variety of treatment options, only 25% of individuals have their condition under control, leading to increased risks for heart disease and stroke. Lexaria's proprietary DehydraTECH™ technology shows promise in delivering effective treatments for hypertension without significant side effects, aiming to compete in a lucrative market. The company holds 21 patents and has over 50 pending globally.

Positive

• Lexaria's DehydraTECH™ technology demonstrates the potential to improve therapeutic responses for treating hypertension.
• The company has a strong intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.
• Lexaria aims to enter a lucrative market currently dominated by major pharmaceutical companies.

Negative

• None.

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. 

To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please visit: https://nnw.fm/ndmMU

Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That’s a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, the no. 1 and no. 5 leading causes of death in the nation each year. To that point, the CDC names hypertension as a primary or contributing cause in nearly half a million deaths annually in the U.S. 

Hypertension treatment options vary tremendously from meditation to conventional drugs, with what looks to be a promising new innovation on the horizon from Lexaria Bioscience Corp. (NASDAQ: LEXX). Lexaria is proving that its proprietary DehydraTECH(TM) technology repeatedly delivers strong therapeutic responses, without the side effects of today’s drugs. Lexaria is looking to throw its hat into the ring with majors in the market today that are making billions of dollars by treating high blood pressure and other leading causes of death.

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.

For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Lexaria Bioscience Corp.'s focus according to the recent press release?

Lexaria Bioscience Corp. focuses on developing treatments for hypertension using its DehydraTECH™ technology, which aims to improve drug delivery without significant side effects.

How prevalent is hypertension in the United States?

Approximately 45% of adults in the United States, equating to about 108 million people, suffer from hypertension.

What are the health risks associated with untreated hypertension?

Untreated hypertension is linked to increased risks for heart disease and stroke, which are leading causes of death in the U.S.

What competitive advantages does Lexaria's DehydraTECH technology offer?

DehydraTECH technology enhances the bioabsorption of cannabinoids and nicotine, potentially allowing for faster onset of effects and improved treatment delivery.

What is Lexaria's patent status?

Lexaria holds 21 granted patents and has more than 50 patents pending worldwide related to its drug delivery technology.